Spero Stock Falls With Two Weeks Left Until FDA Decision
Spero Therapeutics shares fell 1.1% to $2.80 Wednesday, underperforming the SPDR S&P Biotech ETF’s 1.5% gain. The FDA is set to decide by June 18 on tebipenem HBr, Spero’s oral antibiotic for complicated urinary tract infections, developed with GSK. Spero ended March with $56.1 million in cash and expects funding to last into 2028.